The Comptroller’s Office detects tons of medical supplies that were not sent to regions, in the Cenares warehouse, in Lima.
The Comptroller’s Office warned that in the warehouse of non-refrigerated products of the National Center for Supply of Strategic Resources in Health (Cenares), located in the district of Lurín (Lima), there are 4,031,043 units of pharmaceutical products, medical devices and supplies, with risk of maturity in the next few months.
Said condition would affect the efforts to attend and improve public health, in addition to the fact that the public purpose for which they were acquired will not be fulfilled. It is medicine intended for the fight against cancer, malaria and rapid tests for COVID-19.
According to the Control Visit Report No. 024-2021-OCI / 5991-SVC, in total there are 75 pharmaceutical products, medical devices and supplies that are valued at S / 5’073,493.11 and are about to expire between the end of May and end of September of this year.
The supervision carried out at the Cenares warehouse allowed detecting that 14 pharmaceutical products have an expiration date of May 31 and among which are: 251,510 units of capecitabine tablets of 500 milligrams (mg), 24,480 units of erlotinib of 150 mg, 22,739 units of 100 mg paclitaxel, among others, which are part of the National Health Strategy for Cancer Prevention and Control.
Cancer
Capecitabine 500 mg is used for the treatment of breast cancer, cancer of the digestive system (colon, rectum, stomach and esophagus) and pancreatic cancer, while erlotinib 150 mg is used in the treatment of lung and pancreatic cancer. . In the case of paclitaxel 100 mg, its use is focused on the treatment of breast, ovarian and lung cancer.
The expiration date of 1,803 rapid test units for COVID-19 will be met in early June. There are also 16 pharmaceutical products that will expire mainly on June 30, such as: 577,600 units of ondansetron of 8 mg, which is used to prevent the effects of cancer treatments, 31,045 units of cytarabine of 500 mg, which is used in treatment of leukemia, among others.
Another 17 products have an expiration date in the last days of July of this year. In this group there are 548,338 units of primaquine phosphate of 15 mg, corresponding to the National Health Strategy against malaria, and 380,750 units of capecitabine of 500 mg, among other pharmaceutical products.
Data
* The control report warns that these events could jeopardize the achievement of the objectives of these pharmaceutical products, medical devices and supplies, and the purpose of the supply for the timely use of these products
* The results of the control visit report were communicated to the Cenares General Directorate so that they can adopt the corresponding corrective measures; the same ones that, until the end of May, have not been communicated in the respective Action Plan.
* As part of the policy of transparency and access to information, the General Comptroller’s Office published this report on the institutional website.
For. Drafting Time
–
